KRAS and neoplasm: These approaches that effectively and simultaneously inhibit MAPK and PI3K pathways might be effective to block YB-1 signaling in other frequently KRAS-mutated tumor entities, i.e., pancreatic, colorectal and lung cancers, as well as in those tumor entities with constitutive activation of the PI3K/Akt pathway.